Active — Not RecruitingPhase 4

Contrast Nephropathy Associated FFA

Turkey (Türkiye)140 participantsStarted 2024-02-01

Plain-language summary

After the use of iodinated contrast agents, there is a risk of developing contrast nephropathy. Limited data in the literature are available on the incidence of contrast nephropathy after fluorescein angiography (FFA), which is an iodine-free organic contrast. Additionally, factors associated with contrast nephropathy after FFA are not clearly understood. Our study aims to evaluate these points.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Over 18 years old. Patients with an indication for FFA. Those who agreed to participate in the study. Exclusion Criteria: * Patients with nephrotoxic drug exposure in the last two weeks * Patients who underwent imaging management requiring the use of other contrast agents in the last month (such as coronary angiography, CT angiography) * Patients with unstable hemodynamics * Patients with obstructive uropathy * Patients with end-stage renal failure with eGFR\<15 * Patients on a routine hemodialysis program

What they're measuring

Contrast Nephropathy associated FFA

Timeframe: 48-72 hours

Trial details

NCT IDNCT06418542

SponsorSaglik Bilimleri Universitesi

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-08-01

View on ClinicalTrials.gov More Contrast-induced Nephropathy trials